Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16402489 | 0.88 | ESR1 (0.36) | HSP90AA1ESR1ESR2CYP2D6P2RX7 | |
| SCHEMBL13848633 | 0.88 | CYP2D6 (0.36) | HSP90AA1ESR1ESR2CYP2D6P2RX7 | |
| SCHEMBL26774452 | 0.85 | CYP2D6 (0.41) | HSP90AA1ESR1ESR2CYP2D6TSHR | |
| SCHEMBL16919622 | 0.83 | CYP2D6 (0.38) | HSP90AA1ESR1ESR2CYP2D6P2RX7 | |
| SCHEMBL22308557 | 0.82 | NR1I2 (0.40) | CYP2D6TSHRALDH1A1FAAH | |
| SCHEMBL26078439 | 0.82 | NR1I2 (0.40) | CYP2D6TSHRALDH1A1FAAH | |
| SCHEMBL24554448 | 0.81 | HSP90AA1 (0.37) | HSP90AA1CYP2D6P2RX7TSHRCYP19A1 | |
| SCHEMBL1890998 | 0.81 | HSP90AA1 (0.37) | HSP90AA1CYP2D6P2RX7TSHRCYP19A1 | |
| SCHEMBL12059428 | 0.81 | HSP90AA1 (0.37) | HSP90AA1CYP2D6P2RX7TSHRCYP19A1 | |
| SCHEMBL13104790 | 0.81 | HSP90AA1 (0.37) | HSP90AA1CYP2D6P2RX7TSHRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339907-A1 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-09-28 | — | — | US | disclosed |
| US-20160008339-A1 | PSORALEN DERIVATIVES FOR PREVENTING OR TREATING HEART FAILURE OR CARDIAC HYPERTROPHY | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-01-14 | — | — | US | disclosed |
| US-8399458-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399458-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| US-7838517-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838517-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-7662971-B2 | enzyme inhibitor for treating sleep disorders | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-10-29 | — | — | US | disclosed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008339-A1 | PSORALEN DERIVATIVES FOR PREVENTING OR TREATING HEART FAILURE OR CARDIAC HYPERTROPHY | PAH, P4HA1, NPR3 | HSP90AA1 659/4885ESR1 1319/4885ESR2 1077/4885 |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | HSP90AA1 969/4885ESR1 2824/4885ESR2 3533/4885 |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | HSP90AA1 969/4885ESR1 2824/4885ESR2 3533/4885 |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | HSP90AA1 1845/4885ESR1 3443/4885ESR2 3729/4885 |
| US-20230339907-A1 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | DHPS, PDXK, NQO1 | HSP90AA1 4562/4885ESR1 4091/4885ESR2 4481/4885 |
| US-20230303566-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | HSP90AA1 855/4885ESR1 2072/4885ESR2 1735/4885 |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | HSP90AA1 3499/4885ESR1 1268/4885ESR2 1283/4885 |
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, CNR2 | HSP90AA1 3021/4885ESR1 1474/4885ESR2 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.